Contents lists available at NCBI

The American Journal of Science and Medical Research

Journal homepage: https://ajsmrjournal.com/

Review Article

Chemistry at the Frontiers of Drug Discovery: Integrating Synthetic Strategies, Computational Experiments, and Pharmacological Insights

Kandukuri Usha Rani

Department of Chemistry, Indira Priyadarshini Govt. Degree College for women, Nampally, Hyderabad, Telangana, India

*Corresponding author:
Kandukuri Usha Rani
E-mail: usha.sreedhu@gmail.com

https://dx.doi.org/10.5281/zenodo.21947762

Received: 22 January 2025;
Accepted: 28 February 2025;
Published: 12 March, 2025

ISSN: 2377-6196
Published by AIRA

Keywords: *Chemistry, Drug Discovery, Computational Experiments, Synthetic Innovation, ADMET Prediction, Network Pharmacology.*

ABSTRACT

Chemistry continues to serve as the foundation of drug discovery, providing the molecular frameworks, synthetic strategies, and analytical tools essential for therapeutic innovation. From classical organic synthesis to modern computational experiments, the discipline has evolved to address the complexity of diseases and the vastness of chemical space. Advances in catalysis, green chemistry, and molecular innovation have expanded accessible scaffolds, enabling the design of structurally diverse compounds with improved pharmacological properties. Computational chemistry has further transformed discovery pipelines, integrating molecular docking, QSAR modeling, and AI-driven simulations to predict drug–target interactions and pharmacokinetics with unprecedented accuracy. These in silico experiments reduce costs, accelerate timelines, and improve success rates by filtering unsuitable candidates early. Natural product chemistry remains a vital source of inspiration, while predictive ADMET models ensure safety and efficacy. Collectively, synthetic innovation and computational approaches highlight chemistry's interdisciplinary role in bridging molecules with medicine. This review explores how chemistry underpins modern drug discovery, emphasizing its integration with computational experiments, sustainable synthesis, and pharmacological insights, ultimately shaping the future of personalized and systems-based therapeutics.

1. Introduction

Chemistry has historically been the backbone of drug discovery, enabling the design, synthesis, and characterization of molecules that address pressing medical needs. Classical organic synthesis provided the earliest frameworks for therapeutic agents, with landmark discoveries such as aspirin and penicillin demonstrating the transformative power of chemical innovation. Over time, medicinal chemistry emerged as a specialized branch, integrating organic synthesis with pharmacology to refine drug candidates for potency, selectivity, and safety (An et al., 2025). The evolution of analytical techniques, including spectroscopy and chromatography, further strengthened chemistry's role in identifying and characterizing bioactive molecules. Today, chemistry operates at the intersection of multiple disciplines, linking molecular design with computational modeling, systems biology, and clinical pharmacology. This interdisciplinary expansion underscores chemistry's enduring relevance, as it continues to provide the structural and mechanistic foundation upon which modern drug discovery is built (Wang et al., 2025).

2. Synthetic Chemistry and Molecular Innovation

Synthetic chemistry remains central to expanding the chemical space available for drug discovery. Advances in organic synthesis, including transition-metal catalysis, asymmetric synthesis, and click chemistry, have enabled the efficient construction of complex molecular architectures (An et al., 2025). These innovations allow chemists to design molecules with enhanced



Figure 1. Workflow of Natural Product Drug Discovery Integrated with Medicinal Chemistry

pharmacological properties, such as improved solubility, bioavailability, and target specificity. Green chemistry principles have further reshaped synthetic strategies, emphasizing sustainability, reduced waste, and environmentally friendly solvents (Banerjee et al., 2025). Recent developments in regioselective and stereoselective catalysis, photocatalysis, and electrocatalysis have expanded the diversity of drug-like molecules, providing scaffolds that can be fine-tuned for therapeutic applications (Yenare et al., 2025). By integrating catalysis with computational design, chemists can now predict reaction outcomes and optimize synthetic routes with greater precision. This molecular innovation not only accelerates discovery but also ensures that chemistry remains a driving force in the development of next-generation medicines (Figure-1).

3. Computational Chemistry and *In Silico* Experiments

Computational chemistry has become indispensable in modern drug discovery, offering predictive insights that complement experimental synthesis. Techniques such as molecular docking, pharmacophore modeling, and QSAR analysis allow researchers to evaluate drug–target interactions virtually, reducing reliance on costly and time-consuming laboratory assays (Path, 2025). Machine learning and deep learning algorithms now enhance docking accuracy, predicting binding affinities and conformational flexibility with remarkable precision (An et al., 2025). Molecular dynamics simulations further refine these predictions, capturing the dynamic behavior of biomolecules under physiological conditions.

In silico experiments also accelerate lead optimization by identifying structural modifications that improve potency and selectivity. AI-driven virtual screening platforms can process millions of compounds, prioritizing those with favorable pharmacokinetic and pharmacodynamic profiles (Wang et al., 2025). These computational approaches not only streamline discovery pipelines but also integrate seamlessly with synthetic chemistry, guiding chemists toward rational design strategies. The synergy between computational and experimental chemistry exemplifies the interdisciplinary nature of modern drug discovery, where predictive modeling informs synthesis and vice versa.

4. Chemistry of Natural Products and Biologically Active Molecules

Natural product chemistry continues to inspire drug discovery, offering structurally diverse scaffolds with unique biological activities. Compounds such as alkaloids, terpenoids, and polyketides have historically yielded breakthrough drugs, and recent advances in metabolomics and high-throughput screening have expanded the accessible chemical space (Butler et al., 2026). Semi-synthetic derivatives of natural products remain crucial, as structural modifications often enhance bioavailability and reduce toxicity.

Modern approaches integrate computational tools with natural product chemistry, enabling virtual screening of phytochemicals against disease targets. This combination allows researchers to identify multi-target interactions, particularly relevant for complex diseases such as cancer and neurodegenerative disorders (Joshi et al., 2024). Sustainable extraction and green chemistry principles further ensure that natural product research aligns with environmental and ethical standards (Banerjee et al., 2025). By bridging traditional knowledge with modern innovation, natural product chemistry continues to enrich medicinal chemistry and drug discovery.

5. ADMET, Pharmacokinetics, and Chemical Predictive Models

ADMET properties—absorption, distribution, metabolism, excretion, and toxicity—are critical determinants of drug success. Advances in machine learning have revolutionized ADMET prediction, offering rapid and accurate assessments of pharmacokinetic profiles (Bang et al., 2025). Multi-task learning models now capture interdependencies among ADME processes, improving drug-likeness classification and reducing attrition rates in clinical trials (Venkataraman et al., 2025).



Figure 2. Integration of Computational Approaches and ADMET Prediction in Modern Drug Discovery

Chemistry plays a central role in ADMET modeling, as molecular descriptors derived from chemical structures inform predictive algorithms. Computational chemistry integrates these descriptors with pharmacological data, enabling early identification of unsuitable candidates (Figure-2). Network pharmacology complements ADMET prediction by mapping drug–target–pathway interactions, offering a systems-level perspective on therapeutic efficacy (Joshi et al., 2024). Together, chemical predictive models and pharmacokinetic insights ensure that drug discovery pipelines are both efficient and safe.

6. Future Directions: Chemistry in Systems Biology and Personalized Medicine

The future of drug discovery lies in integrating chemistry with systems biology and personalized medicine. Advances in omics technologies—genomics, proteomics, and metabolomics—provide vast datasets that, when combined with chemical modeling, enable precision drug design (Wang et al., 2025; Munipally et al., 2020; Namthabad et al., 2013; Swapna et al., 2024). Chemistry contributes by designing molecules tailored to individual genetic and metabolic profiles, paving the way for personalized therapeutics.

Network pharmacology and computational simulations further enhance this integration, identifying multi-target interactions and predicting patient-specific responses. Sustainable chemistry practices, including bio-based synthesis and green catalysis, ensure that innovation aligns with environmental responsibility (Yenare et al., 2025). As chemistry continues to evolve, its role in systems biology and personalized medicine will expand, reinforcing its position as the bridge between molecular design and clinical application.

7. Conclusion

Chemistry remains the unifying discipline that connects molecular innovation with therapeutic application. From synthetic methodologies and natural product chemistry to computational experiments and ADMET modeling, chemistry provides the tools and frameworks essential for drug discovery. Its interdisciplinary integration with pharmacology, systems biology, and personalized medicine underscores its enduring relevance. As advances in catalysis, computational modeling, and sustainable practices continue to reshape the field, chemistry will remain at the forefront of drug discovery, ensuring the development of safer, more effective, and personalized medicines (An et al., 2025; Butler et al., 2026; Porika et al., 2014; Sucharitha et al., 2013).

Conflicting Interests

The authors have declared that no conflicting interests exist.

References

[1] An, Q., Huang, L., Wang, C., Wang, D., & Tu, Y. (2025). New strategies to enhance the efficiency and precision of drug discovery. Frontiers in Pharmacology, 16, 1550158. https://doi.org/10.3389/fphar.2025.1550158.

[2] Banerjee, S., Periyasamy, S., Muthukumaradoss, K., Deivasigamani, P., & Saravanan, V. (2025).

Revolutionizing organic synthesis through green chemistry: Metal free, bio based, and microwave assisted methods. Frontiers in Chemistry, 13, 1656935. https://doi.org/10.3389/fchem.2025.1656935

[3] Bang, D., Kim, J., Song, H., & Kim, S. (2025). ADME drug likeness: Enriching molecular foundation models via pharmacokinetics guided multi task learning. Bioinformatics, 41(Suppl_1), i352–i361. https://doi.org/10.1093/bioinformatics/btaf259

[4] Butler, M. S., Capon, R. J., Blaskovich, M. A. T., & Henderson, I. R. (2026). Natural product derived compounds in clinical trials and drug approvals. Natural Product Reports, 43(1), 20–88. https://doi.org/10.1039/d5np00031a

[5] Gujjeti, R. P., & Estari Mamidala, E. M. (2017). Anti-HIV activity of phytosterol isolated from Aerva lanata roots. Pharmacogn J, 9(1),112-116. https://doi.org/10.5530/pj.2017.1.19

[6] Gujjeti, R. P., Namthabad, S., & Mamidala, E. (2014). HIV-1 reverse transcriptase inhibitory activity of Aerva lanata plant extracts. BMC Infectious Diseases, 14(Suppl. 3), P12. https://doi.org/10.1186/1471-2334-14-S3-P12

[7] Gujjeti, R. P., Namthabad, S., & Mamidala, E. (2014). HIV-1 reverse transcriptase inhibitory activity of Aerva lanata plant extracts. BMC Infectious Diseases, 14(Suppl. 3), P12. https://doi.org/10.1186/1471-2334-14-S3-P12 https://doi.org/10.1016/j.medidd.2025.100223

[8] Joshi, C. P., Baldi, A., Kumar, N., & Pradhan, J. (2024). Harnessing network pharmacology in drug discovery: An integrated approach. Naunyn Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03625-3

[9] Lunavath, V., & Mamidala, E. (2010). Preliminary phytochemical screening and antibacterial studies of the leaves of Eclipta alba (L.). International Journal of Pharma and Bio Sciences, 4(3), 380–384.

[10] Munipally Praveen Kumar, Poornima, Estari Mamidala, Khalid Al-Ghanim, Fahad Al-Misned, Zubair Ahmed, Shahid MahboobMamidala, E., (2020). Effects of D-Limonene on aldose reductase and protein glycation in diabetic rats. Journal of King Saud University-Science.–Science 32, 1953–1958. https://doi.org/10.1016/j.jksus.2020.01.043

[11] Namthabad, S., & Mamidala, E. (2014). Molecular docking of HIV-1 protease using alkaloids from Tinospora cordifolia. International Journal of Research and Applications, 1(1), 12–16.

[12] Path, I. (2025). Revolutionizing pharmacology: AI powered approaches in molecular modeling and ADMET prediction. Medicine in Drug Discovery, 28, 100223.

[13] Porika, R., Poojari, S., Lunavath, V., & Mamidala, E. (2014). Preliminary phytochemical investigation and TLC analysis of Physalis angulata fruit extract. IOSR Journal of Pharmacy and Biological Sciences, 9(2), 11–14.

[14] Sucharitha, E., & Estari, M. (2013). Evaluation of antidiabetic activity of medicinal plant extracts used by tribal communities in rural areas of Warangal district, Andhra Pradesh, India. Biology and medicine, 5, 20-25

[15] Swapna, K., Srujana, M., & Mamidala, E. (2024). Identification of steroidal cardenolides from Calotropis procera as novel HIV-1 protease inhibitors: A molecular docking and molecular dynamics simulation study. The Indian Journal of Medical Research, 160(1), 78–86. https://doi.org/10.25259/IJMR_2115_23

[16] Venkataraman, M., Rao, G. C., Madavareddi, J. K., & Maddi, S. R. (2025). Leveraging machine learning models in evaluating ADMET properties for drug discovery and development. ADMET & DMPK, 13(3), 2772. https://doi.org/10.5599/admet.2772

[17] Wang, D., Tu, Y., & Dong, Y. (2025). Advances in drug discovery methodologies. Nature Reviews Drug Discovery, 24(11), 1550–1568. https://doi.org/10.1038/s41573-025-00456-9

[18] Yenare, P. P., Patare, R. D., Sonawane, B. P., & Sanap, K. K. (2025). Green chemistry innovation: Sustainable catalysis and strategic future directions. Catalysis Science & Technology, 15(24), 7295–7323. https://doi.org/10.1039/d5cy00559k